Single-patient use
Designed for one patient and not intended for reuse.
For healthcare organizations
A practical first step for product review.
Akoya offers product samples, a brief staff demonstration, and a flexible one-site evaluation framework for organizations reviewing patient-comfort tools in selected needle-based workflows.
Product review summary
Clear product facts for an initial conversation.
Akoya Eye Shield is an optional visual barrier. Each healthcare organization and clinical team determines whether, where, and how it is appropriate to evaluate or use the product.
Nonsterile
Supplied nonsterile. Site-specific handling and disposal requirements remain under organizational review.
Latex-free
The current marketed product is represented by Akoya as latex-free.
Assembled in the USA
Currently available by quote in quantities aligned with organizational needs.
Settings proposed for organizational review
Selected workflows involving activity below eye level.
Potential settings have not all been clinically evaluated with Akoya Eye Shield. They are presented for review by the participating organization's clinical, compliance, and procurement teams.
IV placement
Optional use for patients who prefer not to see peripheral IV access activity.
Port access
Potential review during selected oncology and infusion access workflows.
Blood draws
Potential review during phlebotomy or other vascular-access encounters.
Needle-based procedures
Potential review during selected injections or image-guided procedures.
Suggested starting framework
A limited, organization-led product evaluation.
A 30-day, one-site starting framework can be adjusted to the organization's patient volume, review process, and operational needs.
Product and staff review
Akoya supplies product samples, current available documentation, and a brief product demonstration focused on fit and positioning.
One-site evaluation
The organization selects the site, patients, workflow, scope, and duration under its own clinical, compliance, privacy, and procurement requirements.
Decision on next steps
The organization determines whether any further review, flexible volume pricing, or paid institutional rollout discussion is appropriate.
Optional feedback support
Akoya can provide a simple draft staff and patient feedback template. The participating organization decides whether feedback is collected and governs all applicable clinical, privacy, compliance, and research requirements. Akoya does not need patient-identifying information for a basic product discussion.
What the evaluation can consider
Workflow fit, staff observations, ease of positioning, product handling, and descriptive patient experience. A limited product evaluation is not presented as proof of clinical effectiveness.
Product resources
Materials for an initial review.
Clinical Product Overview
A concise, organization-neutral product sheet covering the design, current product facts, evaluation pathway, early feedback limitations, and contacts.
Download the product overviewPatent record
Public record for U.S. Patent No. 12,629,282 B1, issued May 19, 2026, naming Drew Richard Zaun and Thomas Raymond Goetz as inventors.
View the public patent recordDirect access to Akoya
Start with Akoya founder Drew Zaun.
Drew is the primary contact for healthcare organizations and brings Tom into product-development questions when helpful. Our response target is within two business days.
Drew Zaun
Founder & Chief Sales & Marketing Officer
Product samples, institutional pricing, evaluation discussions, and purchasing.
Contact DrewTom Goetz
Co-Owner & Head of Product
Tom supports product design, fit, documentation, and evaluation questions behind the scenes. Drew coordinates the conversation.
Important: Akoya Eye Shield is presented as a patient-comfort product and optional visual barrier. No clinical outcome is guaranteed. The issued patent documents intellectual property and does not establish clinical effectiveness, safety, or regulatory clearance. Each organization is responsible for its own product, clinical, compliance, and procurement review.